| Biomarker ID | 413 |
| PMID | 19157448 |
| Year | 2009 |
| Biomarker | PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (PSA):-ID regulation of gene expression,Prostate cancer,Androgen receptor proteolysis and transcription regulation,Androgen receptor signaling, proteolysis, and transcription regulation,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Recurrence Vs No recurrence for 5 years |
| Type of Biomarker | Prognostic |
| Cohort | Study compared 52 men who experienced Biochemical Recurrance of Prostate Cancer with 52 patients who remained biochemical recurrence-free for approximately 5 years after radical retropubic prostatectomy. 30 matched pair of Recurrant vs Non- reccurant were selected for training, and the rest 22 pairs were used as testing. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Training: 0.667; Testing: 0.691 |
| Accuracy | NA |
| Level Of Significance | Training: p=0.012 Testing: p=0.011 |
| Method Used | Mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | KLK3, C4A, SERPINA5 |